APEX-Agents
GPT-5.4 on World125_Task01_NA
Grader rubric
Criteria verdict
States that Impact Therapeutic is a company that primarily sells branded drugs
States the average of COGS as a share of revenue for companies that primarily sell branded drugs is 23%
States that the global COGS as a share of revenue for Impact Therapeutics in 2024 is higher than the average of 23%
States that the US COGS as a share of revenue for Impact Therapeutics in 2024 is higher than the average of 23%
Prompt excerpt
Task context
Using the 2024 annual report, identify whether Impact Therapeutics sells primarily branded drugs. A company sells primarily branded drugs if the majority of drugs have launch dates within the last 7 years. Please use the BCG report to determine the average COGS as a % of revenue for competitors in Impact Therapeutics' segment, based on whether they sell primarily generic drugs, branded, or a mix. Round to the nearest %. In both the global and US geos, state whether Impact Therapeutics is above the segment average calculated from the data in the BCG report. Write your response as a reply to me here.
Response trace
Agent response, tools, files, and edits
On a phone, the interactive viewer works best full-screen — pick the narrative report or the files & trajectory workspace.
Why Eval exists · why Workspace exists
Public evidence and cloud agents are the same harness.
Eval exists so scores are inspectable—tasks, trajectories, artifacts, and rubric verdicts anyone can open.Workspace exists so people can automate real file work with that harness, and so Raycaster never evaluates work it cannot perform.